-
Ruxolitinib: From JAK Biology to Immune Translation
2026-08-24
Ruxolitinib (INCB018424) is more than a selective JAK1/2 kinase inhibitor: it is a mechanistic tool for connecting JAK-STAT signaling pathway inhibition with progenitor-cell biology and tumor immune remodeling. This article outlines experimental strategies for myelofibrosis research, oncogenic JAK2 fusion protein studies, and combination immunotherapy models while distinguishing biochemical potency from translational evidence.
-
Bufalin: A Mechanistic Roadmap for TNBC Research
2026-08-24
Bufalin is more than a cardiotonic steroid with broad anticancer activity: emerging evidence positions it as a mechanism-led research probe that can connect direct target engagement, protein degradation, apoptosis, and translational modeling in triple-negative breast cancer. This article examines how STK33 biology, assay design, formulation discipline, and model selection can turn a natural-product signal into a more rigorous development hypothesis.
-
Honokiol Workflows for Cancer Drug Response
2026-08-23
Honokiol can help researchers separate growth inhibition, cell killing, NF-κB signaling, and oxidative-stress effects in cancer and inflammation models. This practical workflow combines dose preparation, time-resolved viability measurements, death confirmation, and mechanism-focused controls to reduce misleading single-assay conclusions.
-
Phosphotungstic Acid Negative Stain Guide
2026-08-22
Phosphotungstic Acid Negative Stain Solution (2%) provides a practical route to high-contrast particle imaging while preserving scientific restraint. This guide connects negative-stain electron microscopy with coronavirus entry research and explains which assay decisions the method can—and cannot—support.
-
Wnt-C59: Practical PORCN Inhibition Workflows
2026-08-21
Wnt-C59 is a high-potency PORCN inhibitor for separating Wnt ligand secretion from downstream pathway activation in reporter, cancer, and exosome-related assays. This guide translates its mechanism into practical workflows, comparative experiments, and troubleshooting strategies while distinguishing established product evidence from proposed applications.
-
GDC-0068 (RG7440) Pan-AKT Inhibitor Guide
2026-08-20
GDC-0068, also known as RG7440, is an ATP-competitive pan-AKT inhibitor for studying PI3K/Akt/mTOR-driven cancer biology. The compound inhibits Akt1, Akt2, and Akt3, shows reported antitumor activity in xenograft models, and requires solvent-specific handling because it is insoluble in water.
-
RNA Pol II Inhibition and Active Cell Death
2026-08-20
Harper et al. show that RNA Pol II inhibition kills cells through an active apoptotic program triggered by loss of hypophosphorylated RNA Pol IIA, rather than through passive depletion of transcripts and proteins. The study defines the Pol II degradation-dependent apoptotic response (PDAR) and provides an experimental framework for distinguishing transcriptional shutdown from regulated cell death in cancer research.
-
Torin2: A Selective mTOR Inhibitor for Cancer Research
2026-08-19
Torin2 is a potent mTOR inhibitor with reported subnanomolar activity, cellular kinase selectivity, and oral bioavailability. Its strongest applications are pathway-dissection studies, medullary thyroid carcinoma models, viability and migration assays, and carefully controlled apoptosis assay workflows.
-
Cyanine 5-dCTP Workflows for DNA Labeling
2026-08-19
Cyanine 5-dCTP enables direct red-fluorescent labeling during enzymatic DNA synthesis, supporting PCR, probe generation, sequencing, and imaging workflows. This guide combines practical starting conditions with the latest DNA-framework findings to improve incorporation, cleanup, signal quality, and assay interpretation.
-
Wnt-C59 as a Causal Probe of Wnt10a Secretion
2026-08-18
Wnt-C59 is a potent PORCN inhibitor for testing whether exosomal Wnt10a secretion causally drives β-catenin-dependent osteogenesis. This article translates recent BMSC findings into a rigorous assay strategy while defining implications for cancer biology.
-
DiscoveryProbe Natural Product Library Plus Workflow
2026-08-18
Turn a chemically diverse natural product library into a staged workflow for enzyme inhibition, parasite phenotyping, and pathway-level validation. This practical guide combines the DiscoveryProbe Natural Product Library Plus with lessons from recent CpAdhE research to improve hit triage, reproducibility, and troubleshooting.
-
Flubendazole as an Autophagy Assay Lens
2026-08-17
Flubendazole can serve as a controlled perturbation for testing how autophagy intersects with tumor-microenvironment signaling. This article translates breast cancer extracellular-vesicle findings into a rigorous assay framework without confusing an autophagy tool with a validated treatment mechanism.
-
P2RX1, Calcium, and Mitochondrial Apoptosis in Ph+ ALL
2026-08-17
This 2025 study identifies P2RX1 as a regulator of tyrosine kinase inhibitor sensitivity in Philadelphia chromosome-positive acute lymphoblastic leukemia, linking purinergic signaling to calcium imbalance, CaMKII activation, PI3K/Akt suppression, and mitochondrial apoptosis. Its findings provide a mechanistic framework for interpreting cell-death responses in Ph+ ALL models while highlighting the need for validation beyond a single engineered cell line.
-
VX-661 and the Next Era of CFTR Rescue
2026-08-16
VX-661 offers more than a folding-rescue readout. By linking F508del CFTR correction to calnexin-dependent proteostasis, variant-aware phenotyping, and exposure sequencing, translational teams can build more predictive cystic fibrosis workflows.
-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-08-15
The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced chronic kidney disease, linking its activity to renal fibrosis, inflammation, epithelial–mesenchymal transition, and Smad3/STAT3 signaling. By testing two SMYD2-directed compounds in animal and tubular epithelial cell models, the work provides a mechanistic framework for evaluating epigenetic intervention in treatment-associated kidney injury.